UiPath Inc. (NYSE:PATH) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lowered its stake in shares of UiPath Inc. (NYSE:PATHFree Report) by 16.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 304,992 shares of the healthcare company’s stock after selling 59,900 shares during the quarter. New York State Common Retirement Fund owned approximately 0.05% of UiPath worth $5,218,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Barclays PLC grew its position in shares of UiPath by 55.2% in the 2nd quarter. Barclays PLC now owns 968,036 shares of the healthcare company’s stock worth $16,039,000 after acquiring an additional 344,499 shares in the last quarter. Geode Capital Management LLC boosted its holdings in UiPath by 4.2% in the second quarter. Geode Capital Management LLC now owns 5,234,696 shares of the healthcare company’s stock worth $86,594,000 after purchasing an additional 210,810 shares during the period. Mackenzie Financial Corp acquired a new position in UiPath in the third quarter worth $2,359,000. D.A. Davidson & CO. boosted its holdings in shares of UiPath by 4.4% in the 2nd quarter. D.A. Davidson & CO. now owns 179,187 shares of the healthcare company’s stock valued at $2,969,000 after buying an additional 7,495 shares during the period. Finally, Ieq Capital LLC boosted its holdings in shares of UiPath by 22.8% in the 3rd quarter. Ieq Capital LLC now owns 1,090,701 shares of the healthcare company’s stock valued at $18,662,000 after buying an additional 202,261 shares during the period. 59.04% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Brad Brubaker sold 105,000 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $24.89, for a total transaction of $2,613,450.00. Following the completion of the sale, the insider now directly owns 597,608 shares in the company, valued at $14,874,463.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CFO Ashim Gupta sold 16,000 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $22.47, for a total value of $359,520.00. Following the completion of the transaction, the chief financial officer now owns 103,505 shares in the company, valued at approximately $2,325,757.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brad Brubaker sold 105,000 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $24.89, for a total value of $2,613,450.00. Following the completion of the transaction, the insider now owns 597,608 shares of the company’s stock, valued at approximately $14,874,463.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 866,000 shares of company stock worth $19,382,520. Corporate insiders own 31.03% of the company’s stock.

Analysts Set New Price Targets

PATH has been the subject of several research reports. JPMorgan Chase & Co. lifted their price target on shares of UiPath from $19.00 to $22.00 and gave the company a “neutral” rating in a report on Friday, December 1st. Morgan Stanley upped their price objective on UiPath from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research note on Friday, December 1st. Canaccord Genuity Group upped their price target on shares of UiPath from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, December 4th. Wells Fargo & Company lifted their price objective on shares of UiPath from $18.00 to $20.00 and gave the company an “equal weight” rating in a research report on Friday, December 1st. Finally, Barclays upped their target price on shares of UiPath from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Friday, January 12th. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $22.32.

Check Out Our Latest Report on UiPath

UiPath Stock Performance

Shares of NYSE PATH opened at $26.35 on Monday. The stock has a fifty day moving average price of $23.86 and a two-hundred day moving average price of $19.25. The firm has a market cap of $14.92 billion, a P/E ratio of -94.10 and a beta of 0.97. UiPath Inc. has a 1 year low of $12.38 and a 1 year high of $26.94.

UiPath (NYSE:PATHGet Free Report) last announced its earnings results on Thursday, November 30th. The healthcare company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.05. UiPath had a negative return on equity of 5.98% and a negative net margin of 12.51%. The business had revenue of $325.92 million during the quarter, compared to analysts’ expectations of $315.54 million. On average, research analysts predict that UiPath Inc. will post -0.22 earnings per share for the current fiscal year.

UiPath Company Profile

(Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Featured Articles

Institutional Ownership by Quarter for UiPath (NYSE:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.